Literature DB >> 8309477

An upstream protein interacts with a distinct protein that binds to the cap site of the human interleukin 1 beta gene.

B G Monks1, B A Martell, J A Buras, M J Fenton.   

Abstract

Interleukin 1 beta (IL-1 beta) is a proinflammatory cytokine that exhibits a wide variety of biological activities. Genomic sequences that mediate the induction of human IL-1 beta gene transcription by lipopolysaccharide and phorbol esters are located more than 2,700 bp upstream of the transcriptional start site (cap site). These upstream elements require additional cap site-proximal (CSP) sequences which are necessary for basal transcription of the human IL-1 beta gene. In addition, these CSP sequences have been shown to mediate both cell type-specific expression of this gene, and trans-activation by some viral proteins. In this study, we report the identification of a novel nuclear protein, termed NF beta C, that binds to a DNA sequence which spans the cap site of the human IL-1 beta gene (positions -12 to +8). We have also identified a second region (positions -305 to -280) containing a putative NF-kappa B binding site. We show here that this region can bind three distinct nuclear proteins. One protein is similar or identical to NF-kappa B, a second protein (termed NF beta B) binds a distinct sequence that substantially overlaps the 5' half of the NF kappa B binding sequence, and a third protein (termed NF beta D) binds a distinct sequence that substantially overlaps the 3' half of the NF kappa B binding sequence. Unlike NF kappa B, NF1 beta B and NF beta D are present in nuclear extracts prepared from unstimulated monocytic cells. Although the NF beta D and NF beta C binding sequences share no significant similarity, each sequence can specifically compete for the binding of either protein to DNA, whereas oligonucleotides containing only the NF kappa B or NF beta B motifs do not compete for the binding of NF beta C or NF beta D. This suggests that NF beta C and NF beta D can specifically interact in vitro, possibly through a common subunit.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8309477     DOI: 10.1016/0161-5890(94)90086-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

2.  MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Authors:  Alan C-Y Hsu; Kamal Dua; Malcolm R Starkey; Tatt-Jhong Haw; Prema M Nair; Kristy Nichol; Nathan Zammit; Shane T Grey; Katherine J Baines; Paul S Foster; Philip M Hansbro; Peter A Wark
Journal:  JCI Insight       Date:  2017-04-06

3.  Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin 1 beta gene expression in human monocytes via a unique promoter sequence.

Authors:  D E Hatzigeorgiou; J Geng; B Zhu; Y Zhang; K Liu; W N Rom; M J Fenton; S J Turco; J L Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Pertussis toxin up-regulates angiotensin type 1 receptors through Toll-like receptor 4-mediated Rac activation.

Authors:  Motohiro Nishida; Reiko Suda; Yuichi Nagamatsu; Shihori Tanabe; Naoya Onohara; Michio Nakaya; Yasunori Kanaho; Takahiro Shibata; Koji Uchida; Hideki Sumimoto; Yoji Sato; Hitoshi Kurose
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

5.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Interactions between pork consumption, CagA status and IL-1B-31 genotypes in gastric cancer.

Authors:  Xiao-Qin Wang; Paul D Terry; Li Cheng; Hong Yan; Jian-Sheng Wang; Wen-An Wu; Sen-Ke Hu
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.